Phosphodiesterase (PDE) targets remain among the most biologically validated yet development-challenging enzyme families in modern drug discovery. The complexity introduced by multiple families, isoforms, splice variants, and tissue-specific regulation has repeatedly proven that early, high-resolution screening and selectivity profiling are not optional—but decisive.
Creative Biogene provides a comprehensive, execution-ready PDE screening and profiling platform designed to help drug discovery teams rapidly identify viable leads, de-risk selectivity liabilities, and generate decision-grade data aligned with downstream pharmacology and development strategies.
Figure 1. Domains of the eleven PDE families and Crystal Structure of the Full-Length PDE2A Dimer. (DeNinno MP. et al., 2012)
Despite decades of research and several landmark approvals, productivity in PDE drug development has historically been limited by:
Creative Biogene's PDE screening strategy is engineered specifically to address these challenges—from biochemical mechanism to cellular context—enabling confident progression beyond early discovery.
Creative Biogene's kinase platforms are engineered to meet these challenges, combining biochemical precision with cellular relevance to generate data that directly informs medicinal chemistry and downstream development. Based on an extensive portfolio of validated kinase assays, Creative Biogene supports kinase programs at every discovery stage:
01
We offer one of the most extensive commercial PDE assay panels, supporting both focused programs and broad selectivity assessment:
02
Creative Biogene delivers end-to-end PDE screening and profiling services, including:
Data Quality First
Radiolabel-based assays and rigorously validated protocols deliver reproducible, decision-grade datasets.
Breadth Without Compromise
Choose from 20+ PDE targets with consistent assay performance across families and isoforms.
Expert-Driven Execution
Our scientists bring 10+ years of hands-on experience in PDE-focused drug discovery, providing not just data, but actionable interpretation and project guidance.
Speed with Scientific Rigor
Optimized workflows enable fast turnaround times without sacrificing assay robustness or biological relevance.
Beyond Screening: Enabling PDE Target Biology
To support deeper mechanistic and translational studies, Creative Biogene also provides a full suite of PDE gene-related research tools, including:
These resources allow seamless expansion from compound screening into target validation, pathway interrogation, and biomarker development.
Custom targets, splice variants, and tailored assay configurations are available upon request.
The future of PDE drug discovery lies beyond simple catalytic inhibition—toward isoform-aware, context-specific modulation strategies. Creative Biogene's screening platforms are designed to support this evolution, helping you generate the data needed to make confident, forward-looking decisions. Tell us your scientific question. We will design the screening strategy to answer it. Contact Creative Biogene today to discuss customized PDE screening and profiling solutions for your program.
Copyright © 2026 Creative Biogene. All rights reserved.